A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Sairah Ahmed et al.|Nature Medicine|2023Cited by 226
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C. Pinnix, Loretta J. Nastoupil, Jillian R. Gunther et al.|Blood Advances|2020Cited by 224
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sattva S. Neelapu, Sairah Ahmed et al.|Blood|2021Cited by 213
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicityUri Greenbaum, Sairah Ahmed, Paolo Strati et al.|Blood Advances|2021Cited by 146
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphomaPaolo Strati, Tom Chi, Loretta J. Nastoupil et al.|Blood Advances|2020Cited by 114